Cravatex Limited

As of June 30, 2026, Cravatex Limited carries a market capitalization of 1.00B, placing it among publicly traded companies globally. Its enterprise value stands at 1.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Cravatex Limited has 2.58M shares outstanding.

As of June 30, 2026, Cravatex Limited trades at a trailing price-to-earnings ratio of 11.66.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.63 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.00B versus a market cap of 1.00B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 199.96M in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Cravatex Limited recorded 20.03M in income tax expense. That works out to an effective tax rate of 18.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 106.07M, leaving 86.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Cravatex Limited's stock has declined approximately 20.84% over the past 52 weeks. The 50-day moving average sits at 341.43, while the 200-day moving average is 357.70.

Over the twelve months ended June 30, 2026, Cravatex Limited generated 1.60B in revenue and converted that into 86.04M in net income, yielding earnings per share of 33.27. EBITDA reached -35.58M, while operating income came in at -50.70M.

Over the twelve months ended June 30, 2026, Cravatex Limited posted a gross margin of 50.79, reflecting its pricing power and cost economics. The operating margin of -3.17 and net profit margin of 5.38 provide insight into operational efficiency.

Cravatex Limited's most recent stock split took place on July 15, 2011 with a 1:2 split ratio.